OSI Pharmaceuticals (OSIP) Announces Consolidation of U.S. Operations
More News related to OSIP
- OSI Pharmaceuticals to Webcast its R&D Analyst Day on Thursday, December 3rd
- OSI Pharma (OSIP) volume and volatility increases into Tarceva committee review
- ODAC to Review Using OSI Pharma's (OSIP) Tarceva as First-Line Therapy for Patients with Advanced Non-Small Cell Lung Cancer
- OSI Pharmaceuticals Announces Tarceva to Be Reviewed by the FDA's Oncologic Drugs Advisory Committee for Use as a First-Line Maintenance Therapy in Advanced Non-Small Cell Lung Cancer
- OSI Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference on Tuesday, November 17, 2009
More News related to Corporate News
- Financial Group Moving Higher Amid BofA TARP Repayment News (BAC, C, WFC, XLF, FAS)
- Lexington Realty Trust (LXP) Sells Office Facility in Columbia, SC
- BofA (BAC) Confirms That It Will Repay $45B in TARP Funds
- EQT Corp.'s (EQT) Board Approves Capital Budget for 2010
- Morgan Stanley (MS) may restructure its real estate fund -WSJ
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced plans to consolidate its U.S. operations onto a single campus located in Ardsley, a community located in the town of Greenburgh in Westchester County, New York.
OSI Pharmaceuticals has signed an agreement to purchase a 43 acre site, which consists of ~400,000 sq.ft. of existing office and laboratory space for $27 million. Additional capital and one time expenses will be incurred, mainly during the latter part of 2009 and first half of 2010.
The Company announced that it expects to realize in excess of $15 million in yearly operating synergies upon completion of the consolidation, which is anticipated by the fourth quarter of 2010.
Related Categories
Corporate NewsStocks Mentioned
+0.14Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
